Janssen begins phase III trial of RSV vaccine for older patients
Having received promising results in a phase IIb study of its RSV vaccine, the Johnson and Johnson-owned pharmaceutical company is now initiating a phase III trial to test the candidate on adults aged 60 and up.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL PEDERSEN
23,000 people will be included in Janssen's phase III study of its vaccine for respiratory syncytial virus, known as RSV. The trial has just begun according to a press release from the company, which is the pharmaceutical arm of the life science group, Johnson and Johnson.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Pfizer begins phase III trial for vaccine against RSV
For subscribers
Analyst thinks RSV vaccine market could reach over USD 10bn
For subscribers
